Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 1/2 7Phase 2 3Phase 1 3

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Lymphoid 1

Conditions

Multiple Myeloma 2Recurrence 1Plasmablastic Lymphoma 1

Interventions

Cyclophosphamide 517Bevacizumab 487Carboplatin 424pembrolizumab 385Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 175Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × belantamab mafodotin × Clear all
NCT05064358 2026-05-05

DREAMM 14

GlaxoSmithKline

Phase 2 Completed
177 enrolled 37 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT04676360 2026-03-13

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Massachusetts General Hospital

Phase 2 Terminated
10 enrolled 11 charts
Lymphoid

Plasmablastic Lymphoma

NCT05117008 2025-01-28

EMBRACE

Medical College of Wisconsin

Phase 2 Terminated
1 enrolled 5 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡